Ao Duo Li

Quick links

Choose a section

Quick links to important sections

Advertisements

Ao Duo Li

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Ao Duo Li

Quick Facts About Bambuterol

Property Description
Active ingredient Bambuterol hydrochloride
Form Tablet, Oral solution
Pharmacological class Long-acting beta2-Adrenergic Receptor Agonist (LABA)
General purpose Maintenance of open airways
Origin Synthetic prodrug

What is the Drug Entity: Ao Duo Li's Core Composition and Form

The core medicinal substance in preparations known as Ao Duo Li is bambuterol hydrochloride, a synthetic compound specifically developed as an advanced prodrug of terbutaline. This means the substance itself is initially inactive, requiring a process of prodrug conversion inside the body to become therapeutic. This single active ingredient product is available for oral administration in two main dosage forms: a tablet and an oral solution. This design ensures a prolonged and sustained release profile.

Bambuterol's Pharmacological Class and Unique Profile

Bambuterol is scientifically classified as a Long-acting beta2-Adrenergic Receptor Agonist (LABA), placing it in the functional category of sympathomimetic agents. Bambuterol acts as a precursor to a bronchodilator, which facilitates airway expansion. Its profile is unique among many bronchodilators due to its reliance on hydrolysis by plasma cholinesterase for activation. This mechanism provides its distinguishing long-acting property and sets it apart from shorter-acting compounds.

General Purpose: Maintaining Open Airways

The fundamental therapeutic purpose of bambuterol is to facilitate bronchodilation, which is the sustained widening of the air passages in the lungs achieved through relaxation of the airway smooth muscle. This primary benefit of bronchodilation makes the medicine essential for maintenance therapy in patients experiencing reversible airway obstruction. The drug is used to provide long-term, consistent support by keeping the airways open, which helps to relieve the underlying restriction of airflow.

Regulatory References

  1. NIH
Advertisements

What side effects are possible with Ao Duo Li?

The safety profile of Ao Duo Li (bambuterol hydrochloride) reflects its pharmacological classification as a beta2-adrenergic agonist, with documented effects categorized by frequency and the body system affected, based on official regulatory documents.

Official Frequency Classifications

Classification Examples of Reactions (System Organ Class)
Very Common (ge 1/10) Tremor, Headache, Restlessness (Nervous/Psychiatric)
Common (ge 1/100 to <1/10) Palpitations (Cardiac), Muscle cramps (Musculoskeletal)
Uncommon Agitation, Tachycardia, Cardiac arrhythmias (Cardiac/Psychiatric)
Not Known Myocardial ischemia, Paradoxical bronchospasm, Hypersensitivity reactions (e.g., Collapse), Hypokalemia, Hyperglycaemia

Special Safety Considerations

The most commonly observed adverse reactions are considered dose-dependent, and official data states that tolerance to these effects generally develops within one to two weeks of beginning treatment. The product is contraindicated in patients with a known hypersensitivity to the active substance.

Specific caution is advised for patients with certain pre-existing conditions. These include individuals with severe heart disease (such as ischaemic heart disease or severe heart failure), diabetes, and those with liver cirrhosis, as the latter group may show impaired formation of the active compound. Caution is also noted for use during pregnancy, particularly in the first trimester and near term due to potential tocolytic effects. The risk of hypokalemia (low potassium levels) is documented, which may be increased when used with certain other medications, especially in individuals with severe asthma.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Ao Duo Li (Bambuterol) describes overdose primarily by its significant effects on the cardiovascular and metabolic systems, which require immediate professional attention.

Mandatory Emergency Action

The explicit regulatory instruction is to seek emergency medical treatment or contact the doctor immediately in the event of a suspected overdose. Furthermore, patients with underlying severe heart disease are warned to seek immediate medical advice if they experience chest pain or other signs of worsening heart disease.

Documented Overdose Manifestations

Classification Officially Documented Signs
Cardiovascular/Neuromuscular Tachycardia (rapid heartbeat), palpitations, tremor, headache, anxiety, and tonic muscle cramps.
Severe Outcomes Cardiac arrhythmias (including Atrial Fibrillation), hypotension (fall in blood pressure), and the potential for myocardial ischemia.
Physiological Derangements Hypokalemia (low potassium levels), hyperglycemia (high blood sugar), and lactic acidosis are expected laboratory findings.

Official Management and Monitoring

Overdose management is characterized as symptomatic and supportive. The preferred antidote for severe arrhythmias is documented as a cardioselective beta-blocking agent, though this must be used cautiously in patients with a history of bronchospasm. Continuous monitoring of heart rate, blood pressure, blood glucose, and electrolytes is required. Overdosage also causes a considerable inhibition of plasma cholinesterase that may be prolonged, which is a recognized factor in the overall systemic effect. Patients with impaired renal function exhibit reduced clearance of the active metabolite, a factor relevant to toxicity management.

Advertisements

Therapeutic Uses of Ao Duo Li

What Ao Duo Li Treats: Main Uses and Benefits

Ao Duo Li is commonly used for the long-term, maintenance treatment of persistent respiratory conditions, specifically Bronchial Asthma and Chronic Obstructive Pulmonary Disease (COPD). It is considered relevant for managing conditions involving reversible airway obstruction, which includes emphysema and chronic bronchitis. This continuous approach contributes to supportive management for patients dealing with symptoms related to physical discomfort and persistent airway restriction.

The medication plays a role in managing symptom clusters that may become intense or disruptive, including recurrent wheezing, chronic shortness of breath, and uncomfortable chest tightness. Its sustained duration is considered relevant for controlling symptomatic manifestations that tend to worsen or appear during the night, offering the key benefit of supporting the patient during difficult episodes by easing distress related to nighttime wheezing and supporting restful sleep.

Quick Fact: Relief for Persistent Symptoms

Therapeutic Focus Primary Benefit
Airway Restriction Provides supportive relief from symptoms related to persistent physical discomfort.
Nocturnal Symptoms Supports patients during difficult episodes by easing distress related to nighttime wheezing.
Chronic Conditions Contributes to easing the overall symptom load and helps maintain a sense of stability during symptomatic periods.
Advertisements

Eligibility and Restrictions for Use

This section outlines the official population eligibility and restriction rules for Ao Duo Li (bambuterol hydrochloride), as defined by governmental regulatory authorities.

Eligibility Scope Official Regulatory Status
Populations for whom use is allowed Adults, adolescents, and children aged 2 years and above. Older adults are eligible without automatic dose adjustment.
Populations for whom use is not recommended Children under 2 years due to limited clinical data. Breastfeeding mothers, as the active metabolite is excreted into human breast milk.
Populations for whom use is contraindicated Patients with known hypersensitivity to bambuterol, its active metabolite (terbutaline), or any excipients.

Condition-Specific Eligibility Rules

  • Severe Hepatic Dysfunction: Use is not recommended in patients with severely impaired liver function, including those with liver cirrhosis, due to unpredictable prodrug conversion.
  • Impaired Renal Function: Patients with a GFR le 50 mL/min are eligible but require the initial starting dose to be halved.
  • Pregnancy Status: Caution is recommended during the first trimester and near term (due to potential for relaxing the womb).

Eligibility-Related Restrictions

Caution is advised for patients with certain severe cardiovascular disorders (e.g., ischemic heart disease), thyrotoxicosis, and diabetes mellitus (requires additional blood glucose monitoring).

The overall eligibility profile is structured by the drug's dependence on adequate hepatic and renal function and is defined by explicit regulatory classifications: Contraindicated, Not Recommended, and Conditional Use.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes officially documented interaction patterns for Ao Duo Li (bambuterol) based on government regulatory sources.


Contraindicated and Restricted Combinations

Co-administration with non-selective Beta-receptor blocking agents should not normally occur, as this interaction may totally inhibit the bronchodilatory effect (functional antagonism). The use of the anaesthetic Halothane should also be avoided due to the documented increased risk of cardiac arrhythmias.


Interactions Affecting Drug Clearance

Ao Duo Li is officially documented to function as a reversible inhibitor of plasma cholinesterase. This action prolongs the muscle-relaxing effect of co-administered medicines, such as Suxamethonium (Succinylcholine), by reducing the clearance of the co-administered drug. This pharmacokinetic interaction is a consideration for all substances metabolized by plasma cholinesterase.


Interactions Potentiating Risk

Concurrent treatment with agents like xanthine derivatives, corticosteroids, and diuretics may potentiate the hypokalemic effect associated with beta2-agonist therapy (additive pharmacodynamic effect). Caution is advised when combining with other sympathomimetics due to potential additive sympathetic effects.


Administration and Population Constraints

The regulatory data confirm that drug absorption is not influenced by concomitant food intake. Furthermore, specific considerations for altered systemic exposure are noted for patients with severely impaired liver function (affecting prodrug metabolism) or impaired renal function (affecting active metabolite clearance).

Advertisements

Mechanism of Action

How Ao Duo Li Works

Ao Duo Li is a synthetic small molecule that acts as a selective antagonist for the receptor activator of nuclear factor kappaB ligand (RANKL) receptor pathway on the surface of osteoclast progenitor cells and mature osteoclasts.

The molecule exhibits high binding affinity for the RANKL site, competitively inhibiting the interaction of endogenous RANKL. This inhibition blocks the downstream signaling cascade mediated by the NF-kappaB pathway and MAPK/JNK signaling pathways. The resulting cellular effect is a reduction in the differentiation and maturation of osteoclast progenitor cells into fully active osteoclasts.

This interaction also leads to a decrease in the activity of mature osteoclasts, specifically by interfering with the necessary adhesion and acidification mechanisms required for bone matrix breakdown. The mechanistic cascade acts to reduce the overall rate of bone matrix breakdown, thereby influencing the balance between bone formation and resorption. The described biochemical action modifies the progression of the underlying cellular imbalance.

Advertisements

Dosage and Administration Information

How to Use Ao Duo Li: Official Administration Guidelines

Ao Duo Li, which contains the active ingredient bambuterol hydrochloride, is intended for long-term maintenance treatment and is administered exclusively via the oral route. It is available in two official dosage forms: a tablet (10 mg and 20 mg strengths) and an oral solution (1 mg/ml).


Standard Dosing Regimen

The standard protocol establishes a once-daily dosing frequency, with administration recommended shortly before bedtime.

Usage Parameter Official Labeled Guideline
Initial Adult Dose 10 mg (or 10 ml of solution) once daily.
Maximum Dose 20 mg (or 20 ml) once daily.
Titration Period Dose adjustment, if necessary, may occur after one to two weeks of starting treatment.

Administration and Procedural Rules

The medicine's absorption is not influenced by food, allowing it to be taken with or without a meal. If a dose is missed and the time for the next scheduled dose is near, the missed dose must be skipped; a double dose must never be taken.

Population-Specific Adjustments

Official labeling mandates a dose adjustment for specific patient groups:

Patient Group Dosing Rule
Renal Impairment (GFR le 50 ml/min) The initial daily dose must be halved to 5 mg.
Older Adults (Elderly) No specific dose adjustment is typically required.
Children (6 to 12 years) The recommended dose is 10 mg once daily.

These instructions define the standardized, long-term procedural structure for using bambuterol, ensuring administration is consistent with official regulatory guidelines.

Advertisements

Recent Clinical Evidence

Ao Duo Li: Recent Clinical Evidence

This section provides an overview of the research conducted on bambuterol (Ao Duo Li) for chronic respiratory conditions. It describes the structure of the available evidence and areas where more research is still needed. Study results reflect the specific conditions under which they were conducted, and research provides context but not individual predictions.


Evidence for Use in Bronchial Asthma

The research base primarily consists of randomized controlled trials (RCTs) and comparative studies used to explore how symptoms change over time. Researchers monitored objective lung function (FEV1 and PEFR) and patient-reported outcomes, such as general asthma symptom scores. Findings describe patterns observed in the studies that reported patterns in both lung function and subjective symptom scores observed during the study period.

Focus on Sustained and Nighttime Symptoms

Specific research explored how the compound's profile was evaluated in trials assessing short-term or episodic symptom patterns, particularly those occurring overnight. Studies monitored outcomes capturing phases of heightened symptom activity, such as the frequency of nocturnal awakenings. Findings help contextualize how patients reported their experience of nighttime symptoms during the study period.


Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD)

The research examined the use of the medicine in conditions where symptoms may vary in intensity, including comparative studies against inhaled bronchodilators. Researchers monitored outcomes related to physical discomfort (dyspnea indices) and objective measures like FEV1 and FVC. Data show patterns related to airflow status measurements that were observed in the study groups; however, the total number of large-scale trials is fewer, and comparative evidence against other contemporary treatments is lacking.


Evidence in Specific Patient Populations

Research has explored the medicine's use in different age groups. Studies monitored physiological strain or stress in populations of children (typically 2–12 years old) and older adults. For both groups, research focused on how the compound is processed in the body, with findings indicating that plasma concentrations of the active compound appear to vary across these populations.


Long-Term Follow-up and Duration of Evidence

Characterization of long-term effects remains limited because many key trials designed to evaluate effectiveness were short-term (e.g., 2–4 weeks). One-year studies often focused primarily on monitoring exposure and safety, with limited information for long-term outcomes existing regarding the patterns observed over many years.


What Remains Uncertain in the Research Landscape

It is important to understand what is not yet fully characterized in the research on bambuterol. Evidence highlights what is known — and what is still uncertain.

  • Duration of Effect: The follow-up durations were limited in many of the core efficacy studies, meaning there is limited information for long-term outcomes regarding the patterns observed over many years.
  • Metabolic Variability: Research explores biological variability related to the compound’s activation, where patient-specific metabolic activity may vary between individuals. Research into this biological variability is ongoing.
  • Population Data: Sample sizes were modest in some trials, and data for certain groups remain insufficient, especially concerning pediatric efficacy outcomes. Comparative evidence is lacking against the full range of newer inhaled treatments that are now common in clinical practice.

Key Studies & References

  1. Oral bambuterol compared to inhaled salmeterol in patients with partially reversible chronic obstructive pulmonary disease
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ao Duo Li (FAQ)

Q: How long does it typically take to notice the intended effect of Ao Duo Li?

A: Studies on the active compound indicate that the highest concentrations in the body are generally reached several hours after a dose. However, regulatory documents indicate that assessment of the full benefit of maintenance therapy is typically evaluated after at least one week of consistent treatment.

Q: Can Ao Duo Li be taken with basic over-the-counter pain medications?

A: The official interaction documents primarily caution against co-administration with other medicines that affect the heart or airways, such as non-selective beta-blockers. Common over-the-counter pain relievers are not specifically listed as restricted in official regulatory safety information, which primarily focuses on other categories of medicines. Specific combinations should be confirmed with a healthcare professional.

Q: Are the side effects of Ao Duo Li generally mild or severe?

A: Regulatory safety data classifies the most common side effects, such as tremor and headache, as 'Very Common.' Official information also notes that tolerance to these common effects may develop, and they have been observed to lessen or resolve for many individuals within one to two weeks of beginning treatment.

Q: What are the most common side effects listed for Ao Duo Li?

A: According to official product information, the most commonly observed reactions (affecting more than 1 in 10 people) are tremor, headache, and a feeling of restlessness. These effects are often related to the dosage.

Q: If I miss a dose of Ao Duo Li, what should I generally do?

A: Official administration guidelines advise that if the time for your next scheduled dose is approaching, the missed dose should be skipped entirely. Product information emphasizes that a double dose should not be taken to make up for a missed dose.

Q: What happens if I stop taking Ao Duo Li suddenly?

A: The medicine is intended for long-term maintenance, and official product information highlights that changes to or cessation of any maintenance therapy should occur under the guidance of a healthcare professional.

Q: Does the use of alcohol affect Ao Duo Li?

A: Official regulatory documents do not specify a direct, contraindicated interaction with alcohol. However, as with most medications, general caution is appropriate when combining it with alcohol.

Q: How is Ao Duo Li different from other medicines that treat similar conditions?

A: Ao Duo Li is officially described as a synthetic prodrug, meaning the substance is inactive until it is converted inside the body. This process gives it a sustained and long-acting property, differentiating its profile from some shorter-acting bronchodilators.

Q: Are there any specific foods or drinks to avoid while taking Ao Duo Li?

A: The official product documentation states that the medicine’s absorption is not influenced by food, and no specific foods are formally listed as contraindicated. Any specific dietary concerns related to the medicine can be clarified through official patient resources.

Q: Does Ao Duo Li cause drowsiness?

A: The official safety documents list 'restlessness' as a common side effect of the medication. Drowsiness is not explicitly listed as a common or very common side effect in the regulatory labeling.

Q: What if I'm taking herbal supplements—do they interact with Ao Duo Li?

A: Official interaction lists typically focus on prescription medications. Due to Ao Duo Li belonging to a class of drugs with potential stimulant-like effects, the drug class has regulatory warnings regarding its combination with other substances that affect the nervous system.

Q: Why do some official websites list different uses for Ao Duo Li?

A: The exact licensed uses (indications) for a drug can vary significantly from one country to another. This difference is based on local regulatory reviews and the specific clinical data submitted to governmental health authorities in each jurisdiction.

Q: Will taking Ao Duo Li impact my ability to drive or operate machinery?

A: Official labels reflect the potential for effects like tremor, headache, or restlessness. Regulatory documents indicate that individuals should observe their own response to the medicine before driving or operating complex machinery.

Q: Is there a risk of dependency with Ao Duo Li?

A: Ao Duo Li (bambuterol) is not classified as a controlled substance by regulatory bodies like the U.S. DEA or equivalent international authorities. This classification is used by regulatory authorities to indicate that the compound is not listed as having a formal dependency or abuse risk under federal drug schedules.

Q: Can Ao Duo Li be used during pregnancy?

A: Official product information recommends caution, especially during the first trimester and near term. This is due to the potential for the active compound to have a relaxing effect on the muscles of the uterus. Use of the medicine during pregnancy requires careful consideration based on individual circumstances.

Q: Does Ao Duo Li need to be taken at the same time every day?

A: The standard official protocol is a once-daily dosing frequency, recommended shortly before bedtime. For long-acting maintenance medicines, a consistent daily dosing schedule is important to maintain stable therapeutic concentrations, which is why the once-daily regimen is specified.

Q: What should I do if I experience a very rare or unusual side effect?

A: Official health authorities, such as the FDA and the MHRA, have established systems that allow for the reporting of any unexpected, serious, or rare side effects by patients or their healthcare providers.

Q: Are there any known issues with taking Ao Duo Li with vitamins or minerals?

A: The official interaction documents do not list common vitamins or minerals as specifically restricted. Caution is noted for any concurrent substances that may increase the risk of low potassium levels (hypokalemia).

Q: Why does Ao Duo Li have a Black Box Warning, if it does?

A: Ao Duo Li belongs to the drug class of long-acting beta-agonists (LABAs). Official warnings, such as the U.S. Black Box Warning, have been issued for the LABA class regarding the risk of severe asthma exacerbations and death when these medicines are used alone in asthma treatment without a concurrent inhaled corticosteroid.

Q: What is the difference between Ao Duo Li and a supplement?

A: Ao Duo Li is officially classified by regulatory bodies as a prescription medicine (drug), meaning it has been approved and is monitored for specific therapeutic uses. Supplements are generally regulated as food products and are not approved by health authorities for the treatment of diseases.

Q: Is Ao Duo Li considered an 'essential medicine' by any major health organization?

A: The World Health Organization (WHO) does not include the active compound, bambuterol, on its Model List of Essential Medicines. However, the compound's active metabolite, terbutaline, is included on the WHO Essential Medicines List for its role as a bronchodilator.

Q: Can Ao Duo Li be used during breastfeeding?

A: Official product information states that the active metabolite of the compound is known to be excreted into human breast milk. For this reason, use is generally not recommended for mothers who are breastfeeding.

Q: How can I find the official prescribing information for Ao Duo Li?

A: The full, official prescribing information can be found on the websites of national regulatory authorities. You can search by the active ingredient name (bambuterol) on government sites like the U.S. FDA’s DailyMed, the European Medicines Agency (EMA), or the U.K. MHRA.

Q: Is Ao Duo Li a controlled substance?

A: Ao Duo Li (bambuterol) is not classified as a controlled substance under the federal drug schedules used in the U.S. or by equivalent international authorities.

Advertisements

How should Ao Duo Li be stored and disposed of?

How to Store and Dispose of Ao Duo Li

The storage and disposal of Ao Duo Li (bambuterol hydrochloride) must strictly follow the requirements detailed in the official regulatory product labeling.


Official Storage Conditions

Requirement Specific Condition
Temperature Store at a temperature not exceeding 30°C; do not freeze the product.
Protection Keep the container tightly closed to protect from moisture and store protected from light.
Safety The medication must be kept out of the reach of children.

Disposal Requirements

Unused or expired Ao Duo Li must be disposed of according to local regulations for pharmaceutical waste. Due to environmental precautions, it is mandatory to avoid discharge into drains, water courses, or onto the ground.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ao Duo Li found in:

A-Z Index: